MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients

Trial Profile

MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2018

At a glance

  • Drugs Alteplase (Primary)
  • Indications Stroke
  • Focus Adverse reactions
  • Acronyms MR WITNESS
  • Most Recent Events

    • 24 Apr 2018 Results (n=80) assessing whether intravenous thrombolysis 4.5 hours from the time of symptom discovery is safe in patients with qDFM, were published in the Annals of Neurology.
    • 05 Apr 2017 New trial record
    • 21 Mar 2017 Planned primary completion date changed from 1 Feb 2016 to 1 Jul 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top